These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 29795696)

  • 1. Correction: Family history and obesity in youth, their effect on acylcarnitine/aminoacids metabolomics and non-alcoholic fatty liver disease (NAFLD). Structural equation modeling approach.
    Romero-Ibarguengoitia ME; Vadillo-Ortega F; Caballero AE; Ibarra-González I; Herrera-Rosas A; Serratos-Canales MF; León-Hernández M; González-Chávez A; Mummidi S; Duggirala R; López-Alvarenga JC
    PLoS One; 2018; 13(5):e0198379. PubMed ID: 29795696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Family history and obesity in youth, their effect on acylcarnitine/aminoacids metabolomics and non-alcoholic fatty liver disease (NAFLD). Structural equation modeling approach.
    Romero-Ibarguengoitia ME; Vadillo-Ortega F; Caballero AE; Ibarra-González I; Herrera-Rosas A; Serratos-Canales MF; León-Hernández M; González-Chávez A; Mummidi S; Duggirala R; López-Alvarenga JC
    PLoS One; 2018; 13(2):e0193138. PubMed ID: 29466466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver fat deposition and mitochondrial dysfunction in morbid obesity: An approach combining metabolomics with liver imaging and histology.
    Calvo N; Beltrán-Debón R; Rodríguez-Gallego E; Hernández-Aguilera A; Guirro M; Mariné-Casadó R; Millá L; Alegret JM; Sabench F; del Castillo D; Vinaixa M; Rodríguez MÀ; Correig X; García-Álvarez R; Menendez JA; Camps J; Joven J
    World J Gastroenterol; 2015 Jun; 21(24):7529-44. PubMed ID: 26140000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correction: Free Fatty Acids Differentially Downregulate Chemokines in Liver Sinusoidal Endothelial Cells: Insights into Non-Alcoholic Fatty Liver Disease.
    McMahan RH; Porsche CE; Edwards MG; Rosen HR
    PLoS One; 2016; 11(12):e0168301. PubMed ID: 27930747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mass-Spectrometry-Based Serum Metabolomics of a C57BL/6J Mouse Model of High-Fat-Diet-Induced Non-alcoholic Fatty Liver Disease Development.
    Lai YS; Chen WC; Kuo TC; Ho CT; Kuo CH; Tseng YJ; Lu KH; Lin SH; Panyod S; Sheen LY
    J Agric Food Chem; 2015 Sep; 63(35):7873-84. PubMed ID: 26262841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correction: Association of inflammatory genes in obstructive sleep apnea and non alcoholic fatty liver disease in Asian Indians residing in north India.
    Bhatt SP; Guleria R; Vikram NK; Vivekanandhan S; Singh Y; Gupta AK
    PLoS One; 2018; 13(8):e0203182. PubMed ID: 30138466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correction: High-normal levels of hs-CRP predict the development of non-alcoholic fatty liver in healthy men.
    Lee J; Yoon K; Ryu S; Chang Y; Kim HR
    PLoS One; 2018; 13(10):e0206834. PubMed ID: 30372496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary Metabolomics in Pediatric Obesity and NAFLD Identifies Metabolic Pathways/Metabolites Related to Dietary Habits and Gut-Liver Axis Perturbations.
    Troisi J; Pierri L; Landolfi A; Marciano F; Bisogno A; Belmonte F; Palladino C; Guercio Nuzio S; Campiglia P; Vajro P
    Nutrients; 2017 May; 9(5):. PubMed ID: 28492501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correction: Modeling the natural history of fatty liver using lifestyle-related risk factors: Effects of body mass index (BMI) on the life-course of fatty liver.
    Aizawa M; Inagaki S; Moriyama M; Asano K; Kakehashi M
    PLoS One; 2019; 14(12):e0226059. PubMed ID: 31790502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correction: Branched chain amino acid transaminase 1 (BCAT1) is overexpressed and hypomethylated in patients with non-alcoholic fatty liver disease who experience adverse clinical events: A pilot study.
    PLOS ONE Staff
    PLoS One; 2019; 14(2):e0212144. PubMed ID: 30721255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction: Prognostic model for psychological outcomes in ambulatory surgery patients: A prospective study using a structural equation modeling framework.
    PLOS ONE Staff
    PLoS One; 2018; 13(6):e0200113. PubMed ID: 29953533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: is universal screening appropriate?
    Byrne CD; Targher G
    Diabetologia; 2016 Jun; 59(6):1141-4. PubMed ID: 27053232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.
    Clemente MG; Mandato C; Poeta M; Vajro P
    World J Gastroenterol; 2016 Sep; 22(36):8078-93. PubMed ID: 27688650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Murine models provide insight to the development of non-alcoholic fatty liver disease.
    Reid DT; Eksteen B
    Nutr Res Rev; 2015 Dec; 28(2):133-142. PubMed ID: 26494024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correction: Public reaction to Chikungunya outbreaks in Italy-Insights from an extensive novel data streams-based structural equation modeling analysis.
    Mahroum N; Adawi M; Sharif K; Waknin R; Mahagna H; Bisharat B; Mahamid M; Abu-Much A; Amital H; Bragazzi NL; Watad A
    PLoS One; 2019; 14(9):e0222865. PubMed ID: 31527901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Application of Metabolomics.
    He X; Ji G; Jia W; Li H
    Int J Mol Sci; 2016 Mar; 17(3):300. PubMed ID: 26999104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deciphering non-alcoholic fatty liver disease through metabolomics.
    Cano A; Alonso C
    Biochem Soc Trans; 2014 Oct; 42(5):1447-52. PubMed ID: 25233430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies.
    Pallayova M; Taheri S
    Clin Obes; 2014 Oct; 4(5):243-53. PubMed ID: 25825857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis of non-alcoholic fatty liver disease (NAFLD).
    Yki-Järvinen H
    Diabetologia; 2016 Jun; 59(6):1104-11. PubMed ID: 27091184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.